Analyst Price Targets — HTFL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:21 am | Rick Wise | Stifel Nicolaus | $40.00 | $25.49 | StreetInsider | HeartFlow (HTFL) Reiterated at Buy by Stifel After SCCT 2026 Meeting |
| May 15, 2026 10:56 am | Larry Biegelsen | Wells Fargo | $37.00 | $32.24 | TheFly | Heartflow price target raised to $37 from $35 at Wells Fargo |
| May 15, 2026 10:49 am | — | Canaccord Genuity | $37.00 | $32.24 | TheFly | Heartflow price target lowered to $37 from $43 at Canaccord |
| January 28, 2026 10:16 am | — | Wells Fargo | $38.00 | $31.21 | TheFly | Heartflow initiated with an Overweight at Wells Fargo |
| September 2, 2025 10:10 am | — | Morgan Stanley | $35.00 | $31.16 | TheFly | Heartflow initiated with an Equal Weight at Morgan Stanley |
| September 2, 2025 9:49 am | — | Canaccord Genuity | $35.00 | $31.16 | TheFly | Heartflow initiated with a Buy at Canaccord |
| September 2, 2025 9:07 am | Rick Wise | Stifel Nicolaus | $35.00 | $31.16 | TheFly | Heartflow initiated with a Buy at Stifel |
| September 2, 2025 9:04 am | Matt O'Brien | Piper Sandler | $38.00 | $31.16 | TheFly | Heartflow initiated with an Overweight at Piper Sandler |
Latest News for HTFL
The medical technology company reported a notable insider sale in recent filings.
I recommend a buy rating for HeartFlow, Inc. due to its strong clinical workflow integration and expanding product suite. HTFL's AI-enabled platform, anchored by FFRCT and Plaque Analysis, drives adoption, monetization, and workflow efficiency in coronary artery disease diagnosis. Plaque Analysis, validated and soon to have its own billing code, broadens HTFL's addressable market and supports incremental revenue…
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of Heartflow Plaque Analysis SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today…
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a pipeline focused on rare diseases.
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HTFL.
U.S. House Trading
No House trades found for HTFL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.